OncoPharm Lenalidomide
7 snips
Jan 4, 2024 Dive into the fascinating world of lenalidomide, a key player in treating hematologic cancers like multiple myeloma. Discover its unique mechanism of action and essential dosing guidelines. The discussion covers crucial safety precautions and the role of the REMS program in patient monitoring. Tune in for insights on the balance between effectiveness and potential toxicity.
AI Snips
Chapters
Transcript
Episode notes
Lenalidomide's Unique MOA
- Lenalidomide acts as a protein degrader by binding cereblon and degrading key transcription factors.
- This disrupts cancer cell growth, primarily in hematologic cancers, and affects immune signaling pathways.
Lenalidomide Indications and Dosing
- Lenalidomide is FDA-approved mainly for multiple myeloma and some lymphomas.
- The typical dose is 25 mg daily for 21/28 days in myeloma treatment, with maintenance at 10 mg daily.
Manage Lenalidomide Risks
- Use strict REMS precautions due to lenalidomide's embryo-fetal toxicity.
- Always use thromboprophylaxis, at least low-dose aspirin, to reduce thrombotic risk.